828 related articles for article (PubMed ID: 21619378)
1. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.
Farnier M
Am J Cardiovasc Drugs; 2011 Jun; 11(3):145-52. PubMed ID: 21619378
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
Lopez D
Drug News Perspect; 2008; 21(6):323-30. PubMed ID: 18836590
[TBL] [Abstract][Full Text] [Related]
3. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
Joseph L; Robinson JG
Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
[TBL] [Abstract][Full Text] [Related]
4. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
5. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
6. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
[TBL] [Abstract][Full Text] [Related]
7. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
Shen L; Peng H; Xu D; Zhao S
Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
[TBL] [Abstract][Full Text] [Related]
8. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
Tibolla G; Norata GD; Artali R; Meneghetti F; Catapano AL
Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):835-43. PubMed ID: 21943799
[TBL] [Abstract][Full Text] [Related]
9. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
Avci A; Demir K; Altunkeser BB
Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
[TBL] [Abstract][Full Text] [Related]
10. PCSK9 gene mutations and low-density lipoprotein cholesterol.
Wu NQ; Li JJ
Clin Chim Acta; 2014 Apr; 431():148-53. PubMed ID: 24518357
[TBL] [Abstract][Full Text] [Related]
11. Anti-PCSK9 therapies for the treatment of hypercholesterolemia.
Hooper AJ; Burnett JR
Expert Opin Biol Ther; 2013 Mar; 13(3):429-35. PubMed ID: 23240807
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.
Lose JM; Dorsch MP; Bleske BE
Pharmacotherapy; 2013 Apr; 33(4):447-60. PubMed ID: 23553812
[TBL] [Abstract][Full Text] [Related]
13. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
Ling H; Burns TL; Hilleman DE
Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
[TBL] [Abstract][Full Text] [Related]
14. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].
Christiansen MK; Jensen HK
Ugeskr Laeger; 2015 Mar; 177(11):. PubMed ID: 25786699
[TBL] [Abstract][Full Text] [Related]
15. PCSK9 inhibition - a novel mechanism to treat lipid disorders?
Banach M; Rizzo M; Obradovic M; Montalto G; Rysz J; Mikhailidis DP; Isenovic ER
Curr Pharm Des; 2013; 19(21):3869-77. PubMed ID: 23286435
[TBL] [Abstract][Full Text] [Related]
16. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
Marais AD; Kim JB; Wasserman SM; Lambert G
Pharmacol Ther; 2015 Jan; 145():58-66. PubMed ID: 25046268
[TBL] [Abstract][Full Text] [Related]
17. PCSK9 antibodies: A new class of lipid-lowering drugs.
Gouni-Berthold I
Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300
[TBL] [Abstract][Full Text] [Related]
18. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
Yang E
Clin Pharmacol Ther; 2015 Dec; 98(6):590-601. PubMed ID: 26369501
[TBL] [Abstract][Full Text] [Related]
19. Update of Clinical Trials of Anti-PCSK9 Antibodies.
Wu NQ; Li S; Li JJ
Cardiovasc Drugs Ther; 2015 Apr; 29(2):159-69. PubMed ID: 25916406
[TBL] [Abstract][Full Text] [Related]
20. PCSK9 inhibition: current concepts and lessons from human genetics.
Rodriguez F; Knowles JW
Curr Atheroscler Rep; 2015 Mar; 17(3):487. PubMed ID: 25637042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
